Articles related to STATINS

Analysis of 285,680 patients shows a 1.03-1.38% reduction in cumulative mortality with rosuvastatin compared to atorvastatin, alongside varying risks for cardiovascular events, liver outcomes, and diabetes.

The PREVENT equation, developed by the American Heart Association in 2023, aims to provide a more accurate cardiovascular risk assessment for today’s population, potentially reducing statin prescriptions by 40%.

Statins remain a cornerstone of cardiovascular disease prevention, but managing potential side effects is key to ensuring patient adherence and optimal outcomes. This article provides a comprehensive overview of statin-associated adverse effects and practical management strategies for clinicians.

The introduction of the PREVENT equations could reduce the number of adults eligible for statin therapy by nearly 40%, impacting clinical guidelines and patient care strategies.

This study evaluates the use of statins for primary prevention of cardiovascular diseases in adults aged 75 years and older, demonstrating a significant reduction in CVD incidence without an increase in severe adverse events. These findings provide real-world evidence to guide clinical decision-making in this underrepresented population.

Statins, although effective at lowering cholesterol, may inadvertently impair immune function by reducing vitamin D synthesis. This opinion piece examines how this could have influenced COVID-19 outcomes, highlighting critical considerations for clinical practice.